As a follow-up to my post from last week, the biotech fund is indeed pushing toward H&S completion. Rather remarkable, considering everything else going on in the market. It’s also kind of ironic, considering how the latest excitement is about the “breakthrough” Covid therapy. In any case, this is almost reaching the failure zone.
Comments
Log in or sign up to join the conversation.